Work

Real-World Evidence Supports Venetoclax as an Additional Option for Patients With t(11;14) Myeloma

Year: 2025

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2025.04.005

Authors: Jules Higué, Gaetan Basile, Titouan Cazaubiel, Julie Gay, Guillaume Béziat, Martin Gauthier, Miguel Carreiro, Noémie Gadaud, François Lifermann, Reza Tabrizi, Benjamin Hébraud, Miguel Granell, Léopoldine Lapierre, Pierre-Luc Mouchel, Pierre Bories, Jill Corre, Cyrille Hulin, Aurore Perrot

Institutions: Institut universitaire du cancer de Toulouse Oncopole, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier de la Côte Basque, Centre Hospitalier d'Albi, Groupe Cahors (France), Centre Hospitalier de Dax –Côte d’Argent, Centre Hospitalier Universitaire de Toulouse

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409430270

FWCI: 1.246

Cites: 10

Cited by: 2

Related to: 10